ArticleScientific reports2017
Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.
Brittany M Duggan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this papercites it